Answers are grounded in this paper and cite their sources.
The global HIV response stands on the threshold of a defining moment. Scientific breakthroughs have ushered in long-acting antiretroviral therapy (ART), which has redefined how HIV can be managed. Injectable formulations, such as cabotegravir–rilpivirine administered every 2 months, have shown high efficacy, safety, and preference across diverse populations and age groups.1–4 Encouragingly, independent studies CARES (NCT05546242), IMPALA (Pan African Clinical Trials Registry 202104874490818), and MOCHA (NCT03497676) have shown that long-acting ART is efficacious, acceptable, and highly preferred in African settings.
No takes yet. Share an insight, caveat, or question.
Kityo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: